Point-of-Care Diagnostic for Trichomonas Vaginalis In response to MedMira’s RVF Technology(R)

HALIFAX, NS / ACCESSWIRE / January 3, 2023 / This day, MedMira Inc. (MedMira) (TSXV:MIR) announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted An infection – (accessible: https://www.mdpi.com/2076-0817/12/1/77), within the special edition of Pathogens by MDPI, a Swiss primarily primarily based clinical journal. The article written by Professor John Alderete from the Faculty of Molecular Biosciences, Washington Train College, outlines the a hit pattern of a POC diagnostic tool for Trichomonas vaginalis in step with MedMira’s RVF Technology®.

Dr. John Alderete found ACT::SOE3, a stable and highly enticing biomarker for Trichomonas vaginalis, to be aged for diagnostic applications. Dr. Alderete required a snappy diagnostic know-how to mobilize his trends and cease a proof-of-thought and the desired validation. MedMira’s Miriad Speedily Vertical Drift Assay Toolkit became created to empower researchers and builders by offering an easy-to-exhaust toolkit containing all parts to invent a major quality quick test.

“We’re impressed by how effective the RVF Technology® can turn an thought precise into a pragmatic product within a brief timeframe. This modern test would be the largest instrument for successfully being care suppliers and other folks contaminated with T. vaginalis that can vastly support to supply a value-efficient and high quality diagnostic instrument for routine and current screening of all age groups and of at-possibility populations,” talked about Dr. John Alderete. “With MedMira’s technical improve and our experience in T. vaginalis learn, I am very hopeful that this unusual test once becomes commercially accessible will toughen the reproductive successfully being of females and men round world.”

Trichomonas vaginalis, the causative agent for trichomoniasis, is the no 1, non-viral Sexually Transmitted Infections (STI) with an estimated incidence of 156 million yearly cases worldwide. Experiences rep shown the extent of the prevalence and incidence numbers of T. vaginalis STIs amongst the age groups 15 to 59 years are high and indicates that this STI is both underreported and neglected. Here’s evident also within the stories that existing the high numbers of undiagnosed, continual infections, in particular within certain racial/ethnic groups, resembling amongst African American citizens in certain settings. Most T. vaginalis STIs are asymptomatic, which contributes to chronic subclinical and detrimental successfully being outcomes for parents. This STI causes maternal and perinatal morbidity and mortality, ectopic pregnancy, pelvic inflammatory disease, detrimental starting up outcomes, and congenital infections. T. vaginalis infections toughen the acquisition of HIV, which is disproportionately elevated amongst African American citizens. Most fresh literature continues to counsel a relation between T. vaginalis and prostate most cancers. These details give a enhance to the need for enhanced routine and current screening to forestall the detrimental morbidity by this STI in our country and worldwide.

“The New three hundred and sixty five days 2023 starts with one more indispensable milestone for our RVF Technology® pattern. The collaboration effort between Dr. Alderete’s community and our product pattern group, clearly demonstrates our management on the diagnostic pattern in addressing the numerous amplify of sexually transmitted infections globally”, Hermes Chan. “This newly developed quick POC test aspects the same advantages for instantaneous turn round and high accuracy as tell in our diverse infectious lines of product resembling HIV, Hepatitis C and Syphilis”.


A degree-of-care (POC) diagnostic is wanted for both females and men to place current screening and surveillance for the no 1, non-viral sexually transmitted infection (STI) attributable to Trichomonas vaginalis. A POC diagnostic test became developed for this STI the usage of the MedMira Speedily Vertical Drift (RVF Technology®) test cartridge with a membrane that functions a vertical procedural/reagent support an eye on line (customarily known as CVL) and noticed actinin known as ACT::SOE3. This protein is a converse diagnostic target for antibody in sera of different folks with trichomoniasis. Serum antibody to ACT::SOE3 is a obvious reaction with

the test agonize. Specificity of ACT::SOE3 became printed with monoclonal antibodies (MAbs) generated to ACT::SOE3. Addition of negative support an eye on serum with MAb 67B reactive to ACT::SOE3 exhibits detection of both ACT::SOE3 and the CVL. Simplest obvious sera of different folks had antibody reactive with ACT::SOE3 and detected the presence of the agonize and the CVL. Negative support an eye on sera were unreactive with ACT::SOE3 and simplest confirmed the presence of the CVL. Importantly, to existing proof-of-principle for POC software program, ACT::SOE3 became detected with the obvious affected person sera spiked with complete blood. The prototypes were broadly validated over the route of 12 months and existing a high sensitivity.

About MedMira

MedMira is a number one developer and manufacturer of Speedily Vertical Drift® diagnostics. The Company’s assessments provide hospitals, labs, clinics and other folks with instantaneous disease diagnosis, resembling HIV, Syphilis, Hepatitis, and SARS-CoV-2, in precisely three easy steps. The Company’s assessments are offered globally below the REVEAL®, REVEALCOVID-19®,Multiplo® and Miriad® manufacturers. In response to its patented Speedily Vertical Drift® Technology, MedMira’s quick HIV test is the finest one on this planet to complete regulatory approvals in Canada, the USA, China and the European Union. MedMira’s company offices and manufacturing facilities are situated in Halifax, Nova Scotia, Canada. For added data seek recommendation from medmira.com. Discover us on Twitter and LinkedIn.

This data originate contains forward‐attempting statements, which involve possibility and uncertainties and assume the Company’s novel expectation concerning future events, at the side of statements concerning in all probability regulatory approval, product originate, future development, and unusual industry opportunities. Right events could additionally materially vary from those projected herein and depend upon pretty about a components at the side of, however no longer restricted to, altering market prerequisites, a hit and successfully timed completion of clinical stories, uncertainties connected to the regulatory approval route of, establishment of company alliances and diverse dangers detailed customarily within the company quarterly filings.

Neither TSX Mission Alternate nor its Regulation Services and products Provider (as that time-frame is printed within the insurance policies of the TSX Mission Alternate) accepts accountability for the adequacy or accuracy of this originate.

MedMira ContactMarkus Meile

Chief Monetary Officer

MedMira Inc.

[email protected]

SOURCE: MedMira, Inc.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button